Welcome to CDC Stacks | Generic Initiation and Adherence to Antidepressant Therapy under Medicare Part D - 41943 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Generic Initiation and Adherence to Antidepressant Therapy under Medicare Part D
  • Published Date:
    Dec 2013
  • Source:
    Am J Manag Care. 19(12):989-998.
Filetype[PDF - 898.62 KB]


Details:
  • Pubmed ID:
    24512035
  • Pubmed Central ID:
    PMC3921685
  • Funding:
    K01 MH090087/MH/NIMH NIH HHS/United States
    R01 AG034056/AG/NIA NIH HHS/United States
    P30 MH090333/MH/NIMH NIH HHS/United States
    K01 HS018546/HS/AHRQ HHS/United States
    P30 MH085943/MH/NIMH NIH HHS/United States
    UL1 RR024156/RR/NCRR NIH HHS/United States
    U18 HS016097/HS/AHRQ HHS/United States
    U48 DP001918/DP/NCCDPHP CDC HHS/United States
    R34 MH082682/MH/NIMH NIH HHS/United States
    R01 HS017695/HS/AHRQ HHS/United States
  • Document Type:
  • Collection(s):
  • Description:
    Objectives

    To assess the effect of initiating antidepressant therapy with a generic prescription on adherence to antidepressant therapy among Medicare patients. A second objective is to assess how the effect might be moderated by the Medicare Part D coverage gap.

    Research Design

    Adherence to antidepressant therapy was measured by (a lack of) disruption in medication use defined by a gap of >=30 days in antidepressant possession and monthly days of possession, both measured over 180 days since antidepressant initiation. We used a 5% random sample of Medicare fee-for-service beneficiaries who received a new depression diagnosis in the first half of 2007 and initiated antidepressant therapy within 60 days (n=16,778). We estimated a Cox proportional hazard model for antidepressant disruption and a mixed-effects linear model for monthly possession. All analyses were stratified by four cohorts defined by Part D low-income subsidy (LIS) status and Medicare entitlement (aged vs. disabled).

    Results

    Generic initiation was associated with improved adherence among all four cohorts, with a stronger effect among the non-LIS patients. Hazard ratios for antidepressant disruption ranged from 0.71 (95% CI: 0.53 to 0.96) among the non-LIS, disabled to 0.88 (95% CI: [0.79, 0.98]) among the LIS, aged. Generic initiation was associated with increases in days of monthly possession in all four cohorts and an additional benefit during the coverage gap for non-LIS patients.

    Conclusions

    Generic initiation can be an important tool to improve adherence to antidepressant treatment among Medicare patients and to mitigate the negative effects of the Part D coverage gap.